314 related articles for article (PubMed ID: 26400847)
21. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
[TBL] [Abstract][Full Text] [Related]
22. HER2 as a target for breast cancer therapy.
Tagliabue E; Balsari A; Campiglio M; Pupa SM
Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
[TBL] [Abstract][Full Text] [Related]
23. Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
Rani S; Corcoran C; Shiels L; Germano S; Breslin S; Madden S; McDermott MS; Browne BC; O'Donovan N; Crown J; Gogarty M; Byrne AT; O'Driscoll L
Cancer Res; 2014 Jul; 74(14):3821-33. PubMed ID: 24876102
[TBL] [Abstract][Full Text] [Related]
24. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy.
Derakhshani A; Rezaei Z; Safarpour H; Sabri M; Mir A; Sanati MA; Vahidian F; Gholamiyan Moghadam A; Aghadoukht A; Hajiasgharzadeh K; Baradaran B
J Cell Physiol; 2020 Apr; 235(4):3142-3156. PubMed ID: 31566722
[TBL] [Abstract][Full Text] [Related]
25. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments.
Barros FF; Powe DG; Ellis IO; Green AR
Histopathology; 2010 Apr; 56(5):560-72. PubMed ID: 20459566
[TBL] [Abstract][Full Text] [Related]
26. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.
Ling Y; Liang G; Lin Q; Fang X; Luo Q; Cen Y; Mehrpour M; Hamai A; Liu Z; Shi Y; Li J; Lin W; Jia S; Yang W; Liu Q; Song E; Li J; Gong C
Mol Cancer; 2022 Jan; 21(1):8. PubMed ID: 34980129
[TBL] [Abstract][Full Text] [Related]
27. Treating the HER2 pathway in early and advanced breast cancer.
Pegram MD
Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
[TBL] [Abstract][Full Text] [Related]
28. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of resistance to HER2 target therapy.
Tortora G
J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
[TBL] [Abstract][Full Text] [Related]
30. Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Lyu C; Ye Y; Lensing MM; Wagner KU; Weigel RJ; Chen S
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34343132
[TBL] [Abstract][Full Text] [Related]
31. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
32. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
Santa-Maria CA; Nye L; Mutonga MB; Jain S; Gradishar WJ
Oncology (Williston Park); 2016 Feb; 30(2):148-55. PubMed ID: 26892151
[TBL] [Abstract][Full Text] [Related]
33. Targeting HER2 in Advanced Breast Cancer.
Zhu X; Joy AA
Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
[TBL] [Abstract][Full Text] [Related]
34. Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients.
Omarini C; Bettelli S; Caprera C; Manfredini S; Caggia F; Guaitoli G; Moscetti L; Toss A; Cortesi L; Kaleci S; Maiorana A; Cascinu S; Conte PF; Piacentini F
Cancer Biol Ther; 2018; 19(10):879-886. PubMed ID: 30067438
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers for Predicting Response to Anti-HER2 Agents.
Varadan V; Sandoval M; Harris LN
Adv Exp Med Biol; 2016; 882():155-67. PubMed ID: 26987534
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of drugs targeting HER-family signalling in cancer.
Montemurro F; Scaltriti M
J Pathol; 2014 Jan; 232(2):219-29. PubMed ID: 24105684
[TBL] [Abstract][Full Text] [Related]
37. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
38. Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
Huang Y; Burns DJ; Rich BE; MacNeil IA; Dandapat A; Soltani SM; Myhre S; Sullivan BF; Lange CA; Furcht LT; Laing LG
BMC Cancer; 2017 Mar; 17(1):199. PubMed ID: 28302091
[TBL] [Abstract][Full Text] [Related]
39. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives.
Soto-Perez-De-Celis E; Loh KP; Baldini C; Battisti NML; Chavarri-Guerra Y; De Glas NA; Hsu T; Hurria A
Expert Opin Investig Drugs; 2018 Oct; 27(10):787-801. PubMed ID: 30196727
[TBL] [Abstract][Full Text] [Related]
40. Resistance to Anti-HER2 Therapies in Breast Cancer.
Rimawi MF; De Angelis C; Schiff R
Am Soc Clin Oncol Educ Book; 2015; ():e157-64. PubMed ID: 25993167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
